IOL Chemicals & Pharmaceuticals Ltd (IOLCP)
₹177.65
Mkt cap
₹5,215 Cr
P/E ratio
24.60
P/B
2.71
Div yield
0.56%
ROE
8.42%
ROCE
11.30%
EPS (TTM)
₹7.22
Book value
₹66
52W range
67–224
Sector
Healthcare
Price history
Previous close
IOL Chemicals & Pharmaceuticals Ltd is a leading pharmaceutical (APIs) company and is a significant player in the specialty chemicals space. It serves the domestic and export market. [1] It is the largest player of Ibuprofen (pain killer) globally with a world market share of 35%. [2]
NSE IOLCPBSE 524164
Health check
Constructive
ValuationCheap
ProfitabilityAverage
GrowthHigh
TechnicalsNeutral
52-week range
−20.69% from high₹178
₹67+164.40% from low₹224
Current
₹177.65
Prev close
₹184.93
Day
−3.94%
Price performance
1D
−3.21%
1W
+9.05%
1M
−11.16%
3M
+23.74%
6M
+87.17%
1Y
+87.98%
YTD
+111.41%
Financials
Revenue, profit & margin
P/E ratio
24.6×
IOLCP is 28% below the sector median of 34.4×
IOLCP24.6×
Sector median34.4×
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 545 | 520 | 504 | 502 | 526 | 523 | 528 | 552 | 568 | 580 | 619 | 756 | 795 | |
| Expenses | 481 | 476 | 454 | 452 | 484 | 476 | 465 | 490 | 510 | 523 | 527 | 653 | 686 | |
| Operating Profit | 64 | 44 | 50 | 51 | 42 | 47 | 63 | 62 | 57 | 57 | 93 | 104 | 109 | |
| OPM % | 12% | 9% | 10% | 10% | 8% | 9% | 12% | 11% | 10% | 10% | 15% | 14% | 14% | |
| Other Income | 7 | 8 | 8 | 7 | 6 | 4 | 5 | 7 | 7 | -6 | 2 | 8 | 6 | |
| Interest | 4 | 4 | 3 | 2 | 4 | 4 | 4 | 4 | 3 | 4 | 3 | 4 | 5 | |
| Depreciation | 16 | 16 | 16 | 17 | 18 | 19 | 19 | 20 | 20 | 20 | 20 | 21 | 22 | |
| Profit before tax | 51 | 32 | 38 | 39 | 26 | 28 | 45 | 46 | 41 | 28 | 71 | 87 | 87 | |
| Tax % | 26% | 28% | 25% | 24% | 26% | 26% | 30% | 25% | 26% | 25% | 25% | 26% | 25% | |
| Net Profit | 38 | 23 | 28 | 30 | 19 | 21 | 32 | 34 | 30 | 21 | 53 | 64 | 65 | |
| EPS in Rs | 1.29 | 0.79 | 0.96 | 1.01 | 0.65 | 0.70 | 1.08 | 1.16 | 1.02 | 0.70 | 1.81 | 2.20 | 2.22 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −1.90% · closed higher next day 0 of last 1
| Q1FY27 | |
|---|---|
| Broadcast | 10 Aug '26 |
| Earnings day | −1.90% |
| +1 day | −2.21% |
| +5 days | −3.91% |
| +15 days | +15.39% |
| +30 days | +19.39% |
| Filing |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Sep 202662.28%Promoter
Promoters62.28%
FIIs7.26%2.39
DIIs0.30%0.13
Public30.16%2.25
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,777.70 | 34.66 | 4,26,530 | 0.90% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹9,780.00 | 87.14 | 2,59,628 | 0.31% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| Torrent Pharma. | ₹4,613.40 | 80.83 | 1,75,479 | 0.82% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,405.50 | 97.00 | 1,29,972 | 0.08% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,245.50 | 25.52 | 1,24,239 | 0.08% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| Dr Reddy's Labs | ₹1,352.00 | 40.30 | 1,12,849 | 0.59% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,378.90 | 35.87 | 1,11,397 | 0.94% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| IOL Chemicals | ₹177.65 | 24.64 | 5,215 | 0.56% | 65 | +116.77% | 795 | +40.09% | 11.29% |
| Median: 158 Co. | ₹426.38 | 34.39 | 1,921 | 0.08% | 14 | +22.08% | 175 | +18.92% | 15.12% |
Filings
Annual reports15
Concall transcripts56
TranscriptSep 2026RECSep 2026TranscriptAug 2026PPTAug 2026RECAug 2026TranscriptMay 2026PPTMay 2026TranscriptFeb 2026PPTFeb 2026TranscriptNov 2025PPTNov 2025TranscriptAug 2025PPTAug 2025TranscriptMay 2025PPTMay 2025RECMay 2025TranscriptFeb 2025PPTFeb 2025TranscriptNov 2024PPTNov 2024TranscriptAug 2024PPTAug 2024RECAug 2024TranscriptMay 2024
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Press Release / Media Release 30 Oct - IOLCP reports Q2/H1 FY27 results, with record revenue, EBITDA and PAT.Board Meeting Outcome for Outcome Of The Board Meeting And Submission Of Unaudited Financial Results Of The Company For The Quarter And Half Year Ended 30Th September 2026 30 Oct - Q2/H1 FY27 results approved on 30 Oct 2026; PAT rose to Rs 129.5 crore.Outcome Of The Board Meeting And Submission Of Unaudited Financial Results Of The Company For The Quarter And Half Year Ended 30Th September 2026 30 OctAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 28 Oct - Schedule of analyst / investor conference call - Q2 & H1 FY27Board Meeting Intimation for Notice Of Board Meeting 23 Oct - Board meeting on 30 Oct 2026 to approve Q2 and half-year unaudited financial results.